NEW YORK – Adaptimmune and Genentech on Tuesday announced a research and development collaboration to advance a personalized allogeneic cell therapy platform, including treatments focused on up to five undisclosed cancer targets.
Roche subsidiary Genentech will pay Adaptimmune $150 million upfront in the deal and another $150 million over the next five years unless the partnership ends earlier. Adaptimmune, which is based in Philadelphia and Oxfordshire, UK, is also eligible to receive up to $3 billion upon meeting certain development, regulatory, and commercial milestones and tiered royalties on net sales of the products developed in the deal in the mid-single to low-double digits.
Adaptimmune has the option to equally share in the costs and profits of the allogeneic products with Genentech. If the company opts in, then 50 percent of the profits and losses from US sales will go to Adaptimmune, as well as regulatory and sales-based milestone payments and royalties on products sold outside of the US.
In order to develop the personalized, off-the-shelf cell therapies, Adaptimmune will produce T cells using its induced pluripotent stem cell-derived allogeneic platform, and Genentech will be responsible for the input T-cell receptors and clinical development and commercialization.
"We believe allogeneic cell therapies could be a game-changing approach for developing personalized therapy platforms based on individual cancer patients' unique needs," James Sabry, Roche's global head of pharma partnering, said in a statement, highlighting that the partnership combines Adaptimmune's allogeneic platform with Genentech's expertise in developing personalized therapies. "It holds the promise to change how we treat cancer and brings us another step closer to making personalized healthcare a reality."